An observational study in Immune Thrombocytopenia and Autoimmune Hemolytic Anemia, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by University Hospital, Toulouse · Observational
CARMEN is a national, real-world clinical registry of all adult patients with incident diagnosis of Immune thrombocytopenia (ITP) or Autoimmune Hemolytic anemia (AIHA) patients in France. It is aimed at describing ITP and AIHA clinical features, assessing the real-world risk-benefit ratio of treatments and adherence to guidelines for ITP and AIHA management.
517 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 161 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 131 across 108 observational studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Browse Purpura, Thrombocytopenic, Idiopathic studies →University Hospital, Toulouse is the lead sponsor of 794 studies on the registry; 214 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Multicentric adult ITP and AIHA case recording in France, selected in centers of the French Referral Autoimmune Cytopenia Network. Both secondary and tertiary (referral) centers are participating (N=44).
Exclusion criteria:
- opposition to data collection
Incidence of Immune thrombocytopenia (ITP) and AIHA
Number of new cases
Time frame: Baseline
Natural evolution and events
Disease duration. Description of bleeding, infection, thrombosis events
Time frame: Baseline and follow-up
Response
platelet count \>30 G/L and no bleeding
Time frame: 15 years
Complete rate
platelet count \>30 G/L and no bleeding
Time frame: 15 years
Treatment lines
% of patients with each treatment by line of treatments
Time frame: 15 years
Adverse drug reactions
% of patients with adverse drug reaction reported by investigators
Time frame: 15 years
Bleeding
% of patients with bleeding during follow-up
Time frame: 15 years
Rescue treatment
% of patients with any treatment added during the exposure of ongoing treatment
Time frame: 15 years
Adherence to ITP management guidelines.
Percentage of patients who benefitted from the recommended examinations to detect secondary ITP and the percentage of patients who benefitted from the recommended first-line and second line treatments
Time frame: 15 years
Events
% of patients with other events of interest like cancer, death, infection, thrombosis
Time frame: 15 years
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic→
University Hospital, Toulouse